Sarah Bolander, DMSc, MMS, PA-C, DFAAPA
Chronic rhinosinusitis with nasal polyps (CRSwNP) is a type 2 inflammatory disease affecting up to 4.2% of people in the United States. CRSwNP results in a variety of symptoms that decrease health-related quality of life (HRQoL). The mainstay of treatment involves intranasal corticosteroids, sinonasal lavage with saline, and fiberoptic endoscopic sinus surgery (FESS). Despite treatment, almost a quarter of patients will suffer a relapse of polyp growth with a reduction of HRQoL within one year. Recently, biologic therapies have been introduced as a new treatment aimed at blocking various parts of the inflammatory pathway responsible for nasal polyp growth. Biologics are both safe and effective in improving HRQoL.
Gonzalez A. Biologics Improve Quality of Life in Patients with Chronic Rhinosinusitis with Nasal Polyps. Lynchburg Journal of Medical Science. 2022; 4(4).
Available when accessing via a campus IP address or logged in with a University of Lynchburg email address.
Off-campus users can also use 'Off-campus Download' button above for access.